aTyr Pharma, Inc.
aTyr Pharma, Inc.（ATYR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ATYR · 截至 2026年6月9日
活动摘要
买入笔数
3
P-Purchase only
卖出笔数
3
近12个月
买卖比
1.00
Buy/Sell (by trades)
整体情绪
aTyr Pharma, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ATYR 季度内部人买卖趋势
ATYR 内幕交易卖出 · ATYR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ATYR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ATYR 高管卖出股份 · ATYR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 27, 2026 | SCHIMMEL PAUL Director | Purchase | 100,000 | $50K | Form 4 |
| Feb 3, 2026 | Shukla Sanjay President and CEO · Director | Option | 10,375 | — | Form 4 |
| Feb 4, 2026 | Shukla Sanjay President and CEO · Director | Sale | 3,745 | $4K | Form 4 |
| Feb 3, 2026 | Broadfoot Jill Marie CFO | Option | 3,750 | — | Form 4 |
| Feb 4, 2026 | Broadfoot Jill Marie CFO | Sale | 1,558 | $2K | Form 4 |
| Feb 3, 2026 | DENYES NANCY General Counsel | Option | 2,687 | — | Form 4 |
| Feb 4, 2026 | DENYES NANCY General Counsel | Sale | 1,118 | $1K | Form 4 |
| Oct 9, 2025 | SCHIMMEL PAUL Director | Purchase | 317,999 | $299K | Form 4 |
| Oct 8, 2025 | SCHIMMEL PAUL Director | Purchase | 682,001 | $612K | Form 4 |
| Mar 17, 2025 | Gross Jane A Director | Purchase | 3,750 | $15K | Form 4 |
| Feb 3, 2025 | Shukla Sanjay President and CEO · Director | Option | 10,375 | — | Form 4 |
| Feb 3, 2025 | Broadfoot Jill Marie CFO | Option | 3,750 | — | Form 4 |
| Feb 4, 2025 | Broadfoot Jill Marie CFO | Sale | 1,254 | $5K | Form 4 |
| Feb 3, 2025 | DENYES NANCY General Counsel | Option | 2,687 | — | Form 4 |
| Feb 4, 2025 | DENYES NANCY General Counsel | Sale | 899 | $3K | Form 4 |
| Jul 24, 2024 | SCHIMMEL PAUL Director | Purchase | 52,300 | $101K | Form 4 |
| Jul 23, 2024 | SCHIMMEL PAUL Director | Purchase | 6,648 | $12K | Form 4 |
| Jul 22, 2024 | SCHIMMEL PAUL Director | Purchase | 41,052 | $72K | Form 4 |
| Jun 5, 2024 | DENYES NANCY General Counsel | Purchase | 5,000 | $9K | Form 4 |
| Nov 1, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Purchase | 24,728 | $119K | Form 4 |
| Nov 8, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Sale | 1,070 | $5K | Form 4 |
| Nov 9, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Sale | 5,819 | $24K | Form 4 |
| Nov 10, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Sale | 5,860 | $23K | Form 4 |
| Nov 13, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Sale | 1,083 | $4K | Form 4 |
| Oct 1, 2017 | EcoR1 Capital Fund Qualified, L.P. 10 percent owner | Purchase | 4,879 | $25K | Form 4 |
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Nov 1
股数
24,728
均价
$4.80
总金额
$119K
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Nov 8
股数
1,070
均价
$4.30
总金额
$5K
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Nov 9
股数
5,819
均价
$4.15
总金额
$24K
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Nov 10
股数
5,860
均价
$4.00
总金额
$23K
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Nov 13
股数
1,083
均价
$3.95
总金额
$4K
EcoR1 Capital Fund Qualified, L.P.
10 percent owner
日期
Oct 1
股数
4,879
均价
$5.05
总金额
$25K
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ATYR 内幕交易
ATYR 内幕交易
aTyr Pharma, Inc.（ATYR）内幕交易数据来源于公司内部人（包括SCHIMMEL PAUL (Director), Shukla Sanjay (President and CEO · Director), Broadfoot Jill Marie (CFO)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。ATYR内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看aTyr Pharma, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ATYR 内幕交易 · 5个问题aTyr Pharma, Inc.（ATYR）的内部人包括高管和董事，如SCHIMMEL PAUL (Director), Shukla Sanjay (President and CEO · Director), Broadfoot Jill Marie (CFO)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026